Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Cancer
Interventions: TAVO412; Drug
Lead sponsor: Tavotek Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: lapatinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 90 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Birmingham, Alabama • Indianapolis, Indiana

Conditions: Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions: AP214, Placebo; Drug
Lead sponsor: Action Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Lipomatosis, Multiple Symmetrical
Interventions: Metreleptin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 60 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: GSK163090; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Peripheral Neuropathy
Interventions: Tai Chi/Qi Gong, α- Lipoic acid, Acupuncture; Behavioral · Dietary Supplement · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Interventions: Obrixtamig - parenteral 1, Obrixtamig - parenteral 2; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Aortic Aneurysm, Abdominal
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Coronary Syndromes
Interventions: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 5
States / cities: Bridgeport, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 2 more

Conditions: Post-ERCP Pancreatitis
Interventions: high dose indomethacin, standard dose indomethacin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 1,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 6
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Alcohol Use Disorder, Alcohol-associated Liver Disease, Alcoholic Cirrhosis, Healthy
Interventions: Pomegranate Dietary Ssupplement; Dietary Supplement
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions: Microdevice; Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiac Arrest, Pulmonary Injury
Interventions: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO), Electrical Impedance Tomography (EIT); Procedure · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Enzastaurin HCL; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Tampa, Florida • Nashville, Tennessee • Houston, Texas

Conditions: Schizophrenia
Interventions: Lurasidone, Quetiapine XR, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 29
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more

Conditions: Fibromyalgia
Interventions: Noninvasive cortical electrical stimulation, Sham treatment; Device
Lead sponsor: McLaren Regional Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
Interventions: ARD-101; Drug
Lead sponsor: Aardvark Therapeutics, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Orange, California • Palo Alto, California + 13 more

Conditions: HIV Infections
Interventions: Saquinavir, Zidovudine, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 17 more

Conditions: Colorectal Cancer
Interventions: everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Neoplasms, Deglutition Disorders
Interventions: EMST; Other
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: Personal Patient Profile - Prostate (P3P), Standard prostate cancer information websites; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Downey, California • Los Angeles, California • Atlanta, Georgia + 1 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions: ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator; Device · Procedure
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIA, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Interventions: TheraBionic P1 Device; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 22 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more

Conditions: Chronic Diabetic Foot Ulcers
Interventions: Extracorporeal Shockwaves; Device
Lead sponsor: Tissue Regeneration Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • The Bronx, New York • Akron, Ohio + 2 more

Search by objective public record fields.

A Study of TAVO412 in Patients with Cancer

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Patient Tolerability Study of GSK163090

Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Clinical Outcomes of Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms

Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

Pomegranate Dietary Supplements in AUD and ALD

Implantable Microdevice In Primary Brain Tumors

Pulmonary Physiologic Assessment of Patients on Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

EMST in Patients Undergoing CRT for HNCA

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

A Study of the TheraBionic P1 Device in Breast Cancer

Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers